COMMUNIQUÉS West-GlobeNewswire

BlossomHill Therapeutics Presents Initial Clinical Data from Dose Escalation in Ongoing Phase 1/1b Trial of Novel Macrocyclic CLK Inhibitor, BH-30236, in Patients with R/R AML or HR-MDS at EHA 2026
11/06/2026
BH-30236 was generally well tolerated and demonstrated preliminary anti-leukemic activity, including in patients previously treated with venetoclax-based regimens, along with favorable pharmacokinetic properties SAN [...]
Bereaved Mothers Give a Gift to Every Grieving Father: The “All Fathers Day” Free Grief Support Bundle. A Documentary Film. A Live Father’s Day Support Group. Free Online Courses. A Dedicated Community. All Free. All at AllFathersDay.com
11/06/2026
My Grief Angels Inc. launches a first-of-its-kind Father’s Day grief support initiative — a complete, free bundle of resources assembled by bereaved mothers, for bereaved fathers. New York, NY, June 11, 2026 (GLOBE [...]
Neion Bio Raises Oversubscribed $23 Million Series A to Advance Biologics Manufacturing Platform and Expand Pipeline
11/06/2026
Financing follows a series of major milestones for Neion Bio, including the company’s emergence from stealth, execution of its first commercial agreement, and continued expansion and advancement of its development [...]
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
11/06/2026
Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on his tenure as Chief Scientific Officer at Sage Therapeutics. CORAL GABLES [...]
Pharvaris Announces Annual General Meeting of Shareholders
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living [...]
Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in [...]
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
11/06/2026
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of Part 1 will assess [...]
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
11/06/2026
New U.S. patents extend protection for cellular immunotherapy applications, immune cell targeting constructs and bizaxofusp combination therapy with anti-VEGF agents for CNS tumors; global portfolio now exceeds 100 [...]
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology
11/06/2026
– High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) – – Strong activity across subgroups, including 70% (14 [...]
Verano Completes 1-for-5 Reverse Stock Split, Advancing the Company’s Path Towards Prospective U.S. Stock Exchange Listing
11/06/2026
CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNO) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that the 1-for-5 reverse stock split (“ [...]
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
11/06/2026
Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the [...]
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
11/06/2026
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide Was Well Tolerated With [...]
Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026
11/06/2026
BERKELEY HEIGHTS, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully-integrated, commercial-stage biotechnology company, today announced that [...]
BrewDog Rolls Back Pint Prices to £2 Across Scotland for 72-Hour Bank Holiday Weekend, Celebrating the National Team’s Return
11/06/2026
ELLON, Scotland, June 11, 2026 (GLOBE NEWSWIRE) -- BrewDog , one of the U.K.’s leading and most recognizable craft beer brands, part of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY), is rolling pint prices back to [...]
Glow Peptide Stack Launched by Koi Peptides for Laboratory Use
11/06/2026
Cheyenne, WY, June 11, 2026 (GLOBE NEWSWIRE) -- Koi Peptides (Koi Research Labs LLC) has launched research-use-only Glow peptide stack, which combines three peptides, GHK-Cu, BPC-157, and TB-500, supplied as a [...]
Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline
11/06/2026
Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, [...]
Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson's Disease
11/06/2026
Collaboration will evaluate Scenic's first-in-class PLA2G15 inhibitor program in Parkinson's disease Leveraging MJFF’s LITE consortium and world-class LRRK2 biology and biomarker infrastructure to test improving [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs [...]
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
11/06/2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant [...]

Pages